Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, Blum HE, Neumann-Haefelin C, Thimme R. · 2014
Read Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. by Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, Blum HE, Neumann-Haefelin C, Thimme R. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4139003.txt.
Introduction
Tobias Flecken, Robert Thimme, and colleagues mapped the killer T cell responses that liver cancer patients naturally mount against tumour proteins. Their study appeared in Hepatology in 2014. Hepatocellular carcinoma is the fifth most common malignancy worldwide, with poor outlook and few treatments, so immune approaches need grounding.
Using overlapping protein fragments and molecular tags, the team tracked CD8 T cells aimed at four cancer-linked proteins in blood, liver, and tumour tissue of a large patient group. Responses to all four existed and followed clear dominance patterns within each protein, though no fixed ranking held between proteins. Broader responses tracked with better survival. Yet the cells produced too little of a key signal, suggesting their attack is blunted and could be strengthened.
Catalog record
| CREATOR | Flecken T, Schmidt N, Hild S, Gostick E, Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, Blum HE, Neumann-Haefelin C, Thimme R. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Immunodominance and functional alterations of tumor‐associated antigen‐specific CD8+ T‐cell responses in hepatocellular carcinoma By Tobias Flecken, Nathalie Schmidt, Sandra Hild, Emma Gostick, Oliver Drognitz, Robert Zeiser, Peter Schemmer, Helge Bruns, Thomas Eiermann, David A. Price, Hubert E. Blum, Christoph Neumann‐Haefelin Published in: Hepatology (Baltimore, Md.) DOI: 10.1002/hep.26731 ABSTRACT Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide with a poor prognosis and limited therapeutic options. To aid the development of novel immunological interventions, we studied the breadth, frequency, and tumor‐infiltration of naturally occurring CD8+ T‐cell responses targeting several tumor‐associated antigens (TAA). We used overlapping peptides spanning the entire alpha‐fetoprotein (AFP), glypican‐3 (GPC‐3), melanoma‐associated gene‐A1 (MAGE‐A1) and New York‐esophageal squamous cell carcinoma‐1 (NY‐ESO‐1) proteins and major‐histocompatibility‐complex‐class‐I‐tetramers specific for epitopes of MAGE‐A1 and NY‐ESO‐1 to analyze TAA‐specific CD8+ T‐cell responses in a large cohort of HCC patients. After nonspecific expansion in vitro, we detected interferon‐γ (IFN‐γ)‐producing CD8+ T cells specific for all four TAA in the periphery as well as in liver and tumor tissue. These CD8+ T‐cell responses displayed clear immunodominance patterns within each TAA, but no consistent hierarchy was observed between different TAA. Importantly, the response breadth was highest in early‐stage HCC and associated with patient survival. After antigen‐specific expansion, TAA‐specific CD8+ T cells were detectable by tetramer staining but impaired in their ability to produce IFN‐γ. Furthermore, regulatory T cells (Treg) were increased in HCC lesions. Depletion of Treg from cultures improved TAA‐specific CD8+ T‐cell proliferation but did not restore IFN‐γ‐production. Conclusion: Naturally occurring TAA‐specific CD8+ T‐cell responses are present in patients with HCC and therefore constitute part of the normal T‐cell repertoire. Moreover, the presence of these responses correlates with patient survival. However, the observation of impaired IFN‐γ production suggests that the efficacy of such responses is functionally limited. These findings support the development of strategies that aim to enhance the total TAA‐specific CD8+ T‐cell response by therapeutic boosting and/or specificity diversification. However, further research will be required to help unlock the full potential of TAA‐specific CD8+ T‐cell responses. (Hepatology 2014;59:1415‐1426) AbbreviationsAFPα‐fetoproteinBCLCBarcelona Clinic Liver CancerCMVcytomegalovirusDMSOdimethyl sulfoxideEBVEpstein‐Barr virusEDTAethylenediaminetetraacetateflu, influenza virus; GPC‐3glypican‐3HBVhepatitis B virusHCChepatocellular carcinomaHCVhepatitis C virusHLAhuman leukocyte antigenIFN‐γinterferon‐γIHLintrahepatic lymphocytesILinterleukinmAbmonoclonal antibodyMAGE‐A1melanoma‐associated gene‐A1NASHnonalcoholic steatohepatitisNY‐ESO‐1New York‐esophageal squamous cell carcinoma‐1PBMCperipheral blood mononuclear cellsPEphycoerythrinPD‐1programmed death‐1PD‐L1programmed death‐ligand 1PFSprogression‐free survivalRFTAradiofrequency thermal ablationRPMIRoswell Park Memorial InstituteTAAtumor‐associated antigenTACEtransarterial chemoembolizationTCRT‐cell receptorTILtumor‐infiltrating lymphocytesTim‐3T‐cell immunoglobulin and mucin‐3Tregregulatory T cell Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. Despite its growing incidence, however, therapeutic options remain limited. Consequently, HCC patients suffer from a high mortality rate.1 New therapies for HCC are therefore urgently required. Immunotherapy is a promising approach for the treatment of HCC.2 The rationale for immunological intervention is based on the presence of high numbers of tumor‐infiltrating T cells in HCC tissue,3 the correlation between the density of lymphocytic infiltrates in HCC lesions and prognosis,4 and, most importantly, the finding that adoptive immunotherapy with interleukin (IL)−2/anti‐CD3‐stimulated autologous lymphocytes lowers postsurgical recurrence rates in humans.5 The central effectors in this scenario are CD8+ T cells that recognize tumor‐associated antigens (TAA) and kill tumor cells. TAA comprise a range of self‐derived proteins rendered immunogenic in tumors either by mutation or aberrant expression.6 A variety of different TAA can spontaneously induce CD8+ T‐cell responses in HCC patients; these include α‐fetoprotein (AFP), glypican‐3 (GPC‐3), melanoma‐associated gene‐A1 (MAGE‐A1), and New York‐esophageal squamous cell carcinoma‐1 (NY‐ESO‐1).7 In addition, TAA‐specific responses can also be boosted in vivo in HCC patients by dendritic cell‐based vaccination with tumor lysate.11 The identification of TAA that are frequently recognized by CD8+ T cells in HCC patients could provide important insights into the choice of appropriate targets for immunotherapy. However, most previous studies focused on single TAA, thus precluding within‐patient comparisons. Indeed, to our knowledge, only two previous studies have compared CD8+ T‐cell responses to different TAA in HCC patients.12 Moreover, these studies were limited to analyses of previously described epitopes restricted by human leukocyte antigen (HLA)‐A*02 and HLA‐A*24, respectively. In this study we used overlapping peptides spanning the entire sequences of AFP, GPC‐3, MAGE‐A1, and NY‐ESO‐1 in a cohort of 96 HCC patients to evaluate naturally occurring CD8+ T‐cell responses against four major HCC‐associated TAA irrespective of HLA restriction. Our results provide the first comprehensive view of TAA‐specific CD8+ T‐cell responses in this setting with attendant implications for therapeutic vaccine design. MATERIALS AND METHODS Patients and Samples Patients were recruited from the Department of Internal Medicine and the Department of Surgery at University Hospital Freiburg and from the Department of General and Transplant Surgery at University Hospital Heidelberg. The study was conducted in accordance with the principles of the Declaration of Helsinki under approval and guidance of local Ethics Committees. Ethylenediaminetetraacetate (EDTA)‐anticoagulated blood, pieces of liver biopsies performed for diagnostic purposes, and samples from liver resections were obtained with written informed consent in all cases. Four‐digit HLA‐genotyping was performed using standard techniques. Experimental Procedures Detailed information on the experimental procedures can be found in the Supporting Online Material. Statistical Analysis Statistical analyses were performed two‐tailed to a significance level of 95% using GraphPad Prism v. 5 (GraphPad Software, La Jolla, CA). The tests used are indicated in the figure legends. All clinical data were obtained from the date of enrollment. Diagnosis of liver cirrhosis was based on patient charts and sonography, with the addition of histology where available. However, since histology was only available for a fraction of patients, liver cirrhosis cannot be completely excluded in all of the patients classified as noncirrhotic. Progression‐free survival (PFS) was calculated as the number of days between the successful therapeutic intervention closest to enrollment and radiological evidence of disease progression. If patients were lost to follow‐up prior to disease progression, data were censored at the date of the last examination. For the Cox proportional hazards model, IBM SPSS Statistics v. 21 (IBM, Armonk, NY) was used. Lines indicate median values unless stated otherwise. RESULTS Study Cohort A total of 96 HCC patients and 15 controls, including two healthy donors, two patients with acute, and 11 patients with chronic hepatitis were recruited for this study. Cohort characteristics are shown in Table 1 and detailed information on HCC patients is available in Supporting Table 2. Most patients had HCC related to chronic alcohol abuse (35.4%), followed by hepatitis C virus infection (HCV; 24.0%), hepatitis B virus infection (HBV; 9.4%), and nonalcoholic steatohepatitis (NASH; 9.4%). For 17 patients (17.7%) no underlying condition could be identified. Most patients (57.3%) were treatment‐naïve at the time of enrollment, pretreated patients had most commonly received transarterial chemoembolization (TACE; 17.7% of all patients). The patients were staged according to the Barcelona Clinic Liver Cancer (BCLC) classification.14 Most patients had early (BCLC A, 28.1%) or intermediate HCC (BCLC B, 36.5%). [Table: Patient Characteristics] Detection of TAA‐Specific CD8+ T‐Cell Responses in Patients With HCC TAA‐specific CD8+ T‐cell responses were analyzed by stimulating antigen‐unspecifically expanded CD8+ T cells derived from peripheral blood mononuclear cells (PBMC) with overlapping peptides spanning the entire length of AFP, GPC‐3, MAGE‐A1, and NY‐ESO‐1 and then evaluated for the production of interferon‐γ (IFN‐γ) by intracellular cytokine staining and flow cytometry. Representative data are shown in Fig. 1A. TAA‐specific responses were detectable in PBMC of 49 patients (51.6%), most of whom recognized one, two, or three peptides (22, 11, and 10 patients, respectively) while only six patients had